<DOC>
	<DOC>NCT02416427</DOC>
	<brief_summary>This pre-surgical, window-of-opportunity study is designed to investigate whether atorvastatin reduces the proliferation marker Ki-67 via modulation of the Hippo transducer TAZ.</brief_summary>
	<brief_title>Targeting the Hippo Transducer TAZ in Breast Cancer With Statins</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<criteria>Inclusion: Signed written informed consent Female aged &gt;18 years and &lt;75 years at the time of the enrolment Histologically confirmed Breast Cancer (BC) independently on the intrinsic subtype Stage IIIa BC patients candidate for elective surgery BC expressing Ki67 ≥ 15% and TAZ &gt; 10% in diagnostic core biopsies Adequate baseline organ function Negative pregnancy test Exclusion: Previous systemic therapy including chemotherapy, hormone therapy and targeted agents Administration of an investigational drug prior to enrolment History of another malignancy, except for a history of completely resected nonmelanoma skin cancer or successfully treated cervical in situ carcinoma Eastern Cooperative Oncology Group (ECOG) performance status ≥2 Subjects who have current active hepatic or biliary disease (with exception of patients with Gilbert's syndrome and asymptomatic gallstones) Serious cardiac illness or medical conditions including but not confined to: history of documented congestive heart failure (CHF) or systolic dysfunction (LVEF &lt;50%); highrisk uncontrolled arrhythmias (ventricular tachycardia, highgrade AVblock, supraventricular arrhythmias which are not adequately controlled); angina pectoris requiring antianginal medication; clinically significant valvular heart disease; evidence of transmural infarction on ECG; poorly controlled hypertension (e.g. systolic &gt;180mm Hg or diastolic &gt;100mm Hg) Have a concurrent disease or condition that may interfere with study participation, or any serious medical disorder that would interfere with the subject's safety (for example, active or uncontrolled infection or any psychiatric condition prohibiting understanding or rendering of informed consent) Current or recent therapy with statins for hypercholesterolemia or other lipidlowering drugs Current or recent therapy with glucoselowering drugs for diabetes Current or recent therapy with strong CYP3A4 inhibitors (e.g., clarithromycin, HIV protease inhibitors, itraconazole) given potential interactions with atorvastatin Current or recent therapy with gemfibrozil or other fibrates given potential interactions with atorvastatin. Patients who are pregnant or breastfeeding</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Atorvastatin</keyword>
	<keyword>TAZ</keyword>
	<keyword>Hippo pathway</keyword>
	<keyword>ki67</keyword>
</DOC>